Menu
Back to Journals » Patient Preference and Adherence » Volume 7
Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
Authors Hua C, Guo H, Guan X, Kong F, Hou R, Zhang X, Li S, Bhavani Viswanathan V
Received 4 August 2013
Accepted for publication 23 August 2013
Published 17 October 2013 Volume 2013:7 Pages 1061—1066
DOI https://doi.org/10.2147/PPA.S52498
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li
Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China
Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients.
Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s α coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test.
Results: Scale reliability was confirmed by Cronbach’s α coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages.
Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China.
Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.